A study to evaluate the relative bioavailability and effect of food on MK-3682B Fixed-Dose Combination Tablet (MK-3682/MK-8408/MK-5172)

MK-3682, MK-5172 and MK-8408 are not registered as medicines. MK-3682 is a
drug that is being developed together with MK-5172 and MK-8408 for the
treatment of hepatitis C virus (HCV) infection. Early HCV infection is
often without symptoms, but chronic infection can lead to serious liver
disease. MK-3682, MK-5172 and MK-8408 inhibit certain proteins of the
HCV virus that contribute to the multiplication of the virus in the body.

- to evaluate the pharmacokinetic (PK) parameters (AUC0-t, AUC0-*, Cmax, C24,
Tmax, and apparent t1/2) of MK-3682 and its circulating metabolites (IDX20664
and IDX23267), MK-5172, and MK-8408 following administration of the fixeddose
combination relative to the individual components when co-administered.

- to estimate the effects of a high fat meal on the pharmacokinetic (PK)
parameters (AUC0-t, AUC0-*, Cmax, C24, Tmax, and apparent t1/2)
of MK-3682 and its circulating metabolites (IDX20664 and IDX23267), MK-5172,
and MK-8408 following administration of the fixed-dose combination relative to
the fasted state.

- To evaluate the safety and tolerability of single oral doses of
co-administered MK-3682, MK-5172, and MK-8408.

This is a single-dose, open-label, randomized, two-period crossover followed by
a fixed third period trial in approximately 22 healthy adult subjects to be
conducted in conformance with Good Clinical Practices.

The study will start with a screening visit. During the screening visit
standard medical assessments including safety laboratory tests (blood draw,
urine collection), an alcohol breath test, urine drug screen, a physical
examination, ECG and a vital signs measurement will be performed. The study has
3 periods. Each period consists of 3 days in clinic (Day -1, Day 1, and Day 2)
and 3 ambulant visits (Day 3, Day 4, and Day 6). Between each period at least
10 washout days are required. Period 3 has 5 ambulant visits, next to Day 3,
Day 4, and Day 6, also on Day 7 and Day 14 ambulant visits are planned. These
are both follow-up visits. During all the (ambulant) visits and during the
stays in the unit, subjects will be asked on a regular base for possible side
effects, blood will be drawnfor safety, PK and measurements and other standard
safety assessment (VS, ECG, lab safety tests,*) can be performed during these
days.

MK-3682: Potential side effects associated with administration of MK-3682 in
single and multiple dose studies in healthy subjects include nausea,
upset stomach, vomiting, stomach discomfort/pain, abnormal feces,
constipation, diarrhea, runny nose, upper respiratory tract infection, cold
sore, skin redness,dry eye, eye itching, drowsiness, lack of energy, dizziness,
body and muscle aches, headache, red eye, feeling of rapid or skipped
heartbeats, and acne.

MK-5172: Side effects reported when MK-5172 was given in combination with other
drugs commonly given to HCV patients (pegylated interferon and ribavirin)
included decrease in the blood cells that carry oxygen, decrease in
blood cells that fight infection, stomach pain, diarrhea, upset
stomach, dry mouth, nausea, vomiting, fever, decreased appetite,back pain,
muscle pain, dizziness, metallic taste, headache, trouble falling asleep or
staying asleep,feeling irritable, weakness, chills, fatigue, flu-like illness,
general pain, cough, shortness of breath, hair loss, dry skin, itchiness,
rash, and pain in the joints.

MK-8408: The following side effects were reported by 2 or more people who were
in single and multiple-dose studies of MK-8408: headache, eye discomfort in
bright light, upset stomach, nausea, vomiting, sore throat, common cold, back
pain, blood in the urine,and increased blood pressure.

The blood collection procedure is not dangerous, but may cause
discomfort or bruising. Occasionally, fainting or an infection at the blood
sampling site can occur.